These studies thus uncover a previously unknown role for ROCK2 dysregulation in ABC-DLBCL and suggest that ROCK inhibition could represent a novel therapeutic option for the treatment of these B-cell malignancies. Here, ROCK2 is linked to diffuse large B-cell lymphoma.